Does Blue Shield of California Cover Wegovy?
The verdict
Conditional on most plans
Blue Shield of California restricts new Wegovy weight-loss starts to BMI 40 or higher (Class III/morbid obesity) since January 1, 2025 — meaning patients at BMI 30–39 who otherwise qualify under the FDA label are excluded from new weight-loss coverage. This is a partial carve-out, not a full exclusion: patients who meet the BMI ≥40 threshold can obtain coverage with prior authorization. California Medi-Cal (Medicaid) dropped GLP-1 obesity coverage effective January 1, 2026. Medicare covers Wegovy for cardiovascular risk reduction only; the Medicare GLP-1 Bridge provides weight-loss access at $50/month starting July 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Shield of California using your member ID.
Key facts
Blue Shield of California restricts new Wegovy weight-loss starts to BMI 40 or higher (Class III obesity) since January 1, 2025 — stricter than the FDA label of BMI ≥30.
Blue Shield of California — formulary and drug coverage policies
California Medi-Cal dropped GLP-1 obesity coverage effective January 1, 2026, joining several other states that reduced coverage amid rising drug costs.
KFF — Medicaid Coverage of and Spending on GLP-1 Medications
The Medicare GLP-1 Bridge launches July 1, 2026 at $50/month for eligible beneficiaries — outside Part D, so the copay does not count toward the $2,100 cap.
CMS.gov — Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Blue Shield of California covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute. Blue Shield of California Medicare members can access Wegovy for the cardiovascular risk-reduction indication (established CVD + overweight/obese status) with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible members weight-loss access to Wegovy at $50/month — outside the Part D benefit, so the $50 copay does not count toward the $2,100 OOP cap or TrOOP, and Extra Help cannot be applied. Bridge eligibility: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are ineligible. NovoCare savings card not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Blue Shield of California restricts weight-loss GLP-1 coverage to Class III (morbid) obesity — a BMI of 40 or higher — for new starts, effective January 1, 2025. This is a harder cutoff than the FDA label (which permits coverage at BMI ≥30, or ≥27 with a weight-related comorbidity). A patient with a BMI of 35 and hypertension who meets the FDA criteria will be denied a new weight-loss start under Blue Shield of California's current policy. Patients above BMI 40 who meet the threshold can obtain coverage with prior authorization. ACA/individual-market plans under Blue Shield of California apply the same BMI ≥40 restriction. Commercially insured members whose plan covers Wegovy (BMI ≥40 met) may use the NovoCare savings card to pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medi-Cal beneficiaries. California Medi-Cal (Medicaid) dropped GLP-1 obesity coverage effective January 1, 2026; non-weight-loss FDA indications remain covered. Verify current plan-specific details on the Blue Shield of CA drug-lookup tool.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 5 requirements selected. Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share for members who meet the BMI ≥40 threshold. NovoCare savings card: commercially insured members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medi-Cal beneficiaries. Confirm your tier and cost-share via the Blue Shield of CA drug-lookup tool.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Verify actual cost-share on the Blue Shield of California member portal or with your pharmacist. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Confirm your BMI against the BMI ≥40 threshold
Blue Shield of California's weight-loss coverage applies only to new starts at BMI 40 or higher. Before requesting a PA, verify your current BMI with your provider. If your BMI is below 40, weight-loss Wegovy coverage is not available for new starts under current policy — even if you have qualifying comorbidities. Check the Blue Shield of CA drug-lookup tool for any policy updates.
- 2
Use the Blue Shield of California drug-lookup tool
Visit blueshieldca.com and use the formulary or drug-lookup search with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm the current tier, PA criteria, and quantity limits for your specific plan. The BMI ≥40 new-start restriction may have been updated since January 2025 — always check the current policy.
- 3
Work with your prescriber on prior authorization
If your BMI is 40 or higher, your prescriber will document it and submit a PA with clinical supporting materials including comorbidities, participation in a weight-management program, and any renewal-specific weight-loss progress. For Medicare members seeking the cardiovascular indication, confirm that established CVD is documented in your clinical record.
Options if Blue Shield of California won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
NovoCare self-pay program (BMI <40 or excluded members)
Patients excluded by the BMI ≥40 threshold can access Wegovy directly through NovoCare Pharmacy at approximately $349/month for standard injection doses. Introductory pricing applies through December 31, 2026. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Medicare GLP-1 Bridge (Medicare members)
Starting July 1, 2026, eligible Medicare members can access Wegovy for weight loss at $50/month through the Bridge program, which operates outside Part D. Eligibility is based on BMI and clinical criteria, not the BMI ≥40 commercial threshold.
Compounded semaglutide
Compounded semaglutide is available without insurance or BMI requirements. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
Blue Shield of California restricts new Wegovy weight-loss starts to a BMI of 40 or higher — Class III (morbid) obesity — effective January 1, 2025. The FDA labels Wegovy for BMI ≥30, or ≥27 with a weight-related comorbidity, so Blue Shield's cutoff is significantly stricter. Patients with BMI 30–39, even with hypertension or type 2 diabetes, are excluded from new weight-loss coverage under this policy. Verify the current threshold on the Blue Shield of CA formulary, as policies can change.
Blue Shield of California ACA/individual-market plans apply the same BMI ≥40 restriction for new weight-loss starts. Patients on ACA exchange plans whose BMI is below 40 are generally excluded from new Wegovy weight-loss coverage. ACA exchange plans are not treated as government programs for the NovoCare savings card, meaning a commercially insured ACA member whose plan does cover Wegovy (BMI ≥40 met) could use the $25/month savings card. Verify on your specific plan's formulary.
California Medi-Cal (Medicaid) dropped GLP-1 obesity coverage effective January 1, 2026. Blue Shield of California members on Medi-Cal plans cannot obtain Wegovy for weight-loss use through Medi-Cal. Non-weight-loss FDA indications for semaglutide — such as type 2 diabetes or the cardiovascular risk-reduction indication — remain covered through Medi-Cal where applicable. Verify current Medi-Cal coverage with your plan.
Both Blue Shield of California and Kaiser Permanente apply a BMI ≥40 weight-loss threshold for new GLP-1 starts since January 2025. The key difference is the network model: Kaiser is a closed-network integrated HMO with regional variation and an intra-molecule step requirement in some regions, while Blue Shield of California is an open-network plan applying the BMI ≥40 rule broadly. If your BMI is below 40, neither plan covers new Wegovy weight-loss starts under current policies.
Blue Shield of California Medicare members who are eligible under the federal Bridge criteria can access the Medicare GLP-1 Bridge at $50/month starting July 1, 2026. Bridge eligibility — based on BMI ≥35 or qualifying clinical conditions — is independent of Blue Shield of CA's commercial BMI ≥40 rule. The Bridge operates outside Part D, so the $50 copay does not count toward your $2,100 Part D OOP cap. Members already on a Part D-covered GLP-1 are not eligible for the Bridge.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes BCBS Michigan Cover Wegovy? 2026 Coverage Guide | Curex
BCBS Michigan ended weight-loss GLP-1 coverage on fully insured plans in 2025. Self-funded groups may opt in. Michigan Medicaid covers Wegovy as preferred.
Read moreDoes Blue Cross MN Cover Wegovy? 2026 Employer Guide | Curex
Blue Cross MN covers Wegovy only where your employer bought the anti-obesity benefit. Not published at drug level — check plan drug lookup and ask HR.
Read moreWhether or not Blue Shield of California covers Wegovy, there's a path that skips insurance
You just saw how tangled Wegovy coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Wegovy. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Shield of California before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.